Pharmacovigilance: A Necessary Tool for Drug Safety Monitoring Globally

Pharmacovigilance

  • Asra Mansuri Department of Hospital Management and Hospice Studies, Jamia Millia Islamia, Jamia Nagar, New Delhi-110025, India
  • Tabrez Uz Zaman Assistant Professor, Department of Hospital Management and Hospice Studies, Jamia Millia Islamia, Jamia Nagar, New Delhi-110025, India

Abstract

Pharmacovigilance, which is like a parasol to define the procedures for monitoring and analysing adverse drug reactions (ADRs), is a crucial part of efficient clinical practise, public health initiatives, and drug control systems. The volume of data processed has increased as a result of the rise in reported adverse drug reactions (ADRs), and understanding pharmacovigilance requires a high degree of skill in order to quickly identify medication hazards and defend the product against an unwarranted removal. An impartial method of evaluation would strengthen the present global network of pharmacovigilance centres, which is managed by the Uppsala Monitoring Centre. This would take into account contentious and significant medication safety problems that might have a negative impact on public health across international borders. Pharmacovigilance has recently focused mostly on identifying previously unrecognised or poorly understood adverse medication occurrences. Pharmacovigilance is a crucial and essential component of clinical research, and it is now expanding in many nations. However, with the turn of the millennium, pharmacovigilance confronts enormous hurdles in aspect of improving safety and monitoring of medications. Today, several pharmacovigilance centres are engaged for drug safety monitoring in this global arena. In this overview, we'll talk about medication safety, the function of international pharmacovigilance centres, the advantages and drawbacks of pharmacovigilance, and how it may be used in the future by the healthcare industry.


Keywords: Drug safety, Adverse drug reaction, Drug Monitoring, Erice declaration, pharmacovigilance

Keywords: Drug safety, Adverse drug reaction, Drug Monitoring, Erice declaration, pharmacovigilance

Downloads

Download data is not yet available.

Author Biographies

Asra Mansuri, Department of Hospital Management and Hospice Studies, Jamia Millia Islamia, Jamia Nagar, New Delhi-110025, India

Department of Hospital Management and Hospice Studies, Jamia Millia Islamia, Jamia Nagar, New Delhi-110025, India

Tabrez Uz Zaman, Assistant Professor, Department of Hospital Management and Hospice Studies, Jamia Millia Islamia, Jamia Nagar, New Delhi-110025, India

Assistant Professor, Department of Hospital Management and Hospice Studies, Jamia Millia Islamia, Jamia Nagar, New Delhi-110025, India

References

1. Strom BL. Overview of automated databases in pharmacoepidemiology. Textbook of pharmacoepidemiology. 2013 Sep 16:118-22. https://doi.org/10.1002/9781118344828.ch08
2. Butlen-Ducuing F, Rivière F, Aarum S, Llinares-Garcia J. European Medicines Agency support mechanisms fostering orphan drug development. Drug News &Perspectives. 2010 Jan 1;23(1). https://doi.org/10.1358/dnp.2010.23.1.1437303 PMid:20155221
3. Giezen TJ, Mantel-Teeuwisse AK, Straus SM, Egberts TC, Blackburn S, Persson I, Leufkens HG. Evaluation of post-authorization safety studies in the first cohort of EU risk management plans at time of regulatory approval. Drug Safety. 2009 Dec;32:1175-87. https://doi.org/10.2165/11318980-000000000-00000 PMid:19916584
4. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. British journal of clinical pharmacology. 2010 Jan;69(1):4-14. https://doi.org/10.1111/j.1365-2125.2009.03537.x PMid:20078607 PMCid:PMC2805870
5. Abenhaim L, Moride Y, Brenot F, Rich S, Benichou J, Kurz X, Higenbottam T, Oakley C, Wouters E, Aubier M, Simonneau G. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. New England Journal of Medicine. 1996 Aug 29;335(9):609-16. https://doi.org/10.1056/NEJM199608293350901 PMid:8692238
6. Kaufman DW, Rosenberg L, Mitchell AA. Signal generation and clarification: use of case-control data. Pharmacoepidemiology and Drug Safety. 2001 May;10(3):197-203. https://doi.org/10.1002/pds.571 PMid:11501331
7. Greene W. The emergence of India's pharmaceutical industry and implications for the US generic drug market.
8. DeStefano F, Tokars J. H1N1 vaccine safety monitoring: beyond background rates. The Lancet. 2010 Apr 3;375(9721):1146-7. https://doi.org/10.1016/S0140-6736(09)61917-6 PMid:19880171
9. Chen RT, DeStefano F, Davis RL, Jackson LA, Thompson RS, Mullooly JP, Black SB, Shinefield HR, Vadheim CM, Ward JI, Marcy SM. The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bulletin of the World Health Organization. 2000;78(2):186-94.
10. Vander Stichele RH, Elseviers MM, Ferech M, Blot S, Goossens H, ESAC Project Group. European surveillance of antimicrobial consumption (ESAC): data collection performance and methodological approach. British journal of clinical pharmacology. 2004 Oct;58(4):419-28. https://doi.org/10.1111/j.1365-2125.2004.02164.x PMid:15373935 PMCid:PMC1884596
11. Martirosyan L, Voorham J, Haaijer‐Ruskamp FM, Braspenning J, Wolffenbuttel BH, Denig P. A systematic literature review: prescribing indicators related to type 2 diabetes mellitus and cardiovascular risk management. Pharmacoepidemiology and drug safety. 2010 Apr;19(4):319-34. https://doi.org/10.1002/pds.1894 PMid:19960483
12. Von Laue NC, Schwappach DL, Koeck CM. The epidemiology of preventable adverse drug events: a review of the literature. Wiener Klinische Wochenschrift. 2003 Jun 15;115(12). https://doi.org/10.1007/BF03040432 PMid:12918183
13. Aneesh TP, Sekhar S, Jose A, Chandran L, Zachariah SM. Pharmacogenomics: the right drug to the right person. Journal of clinical medicine research. 2009 Oct;1(4):191.
14. Brockmöller J, Tzvetkov MV. Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment. European journal of clinical pharmacology. 2008 Feb;64:133-57. https://doi.org/10.1007/s00228-007-0424-z PMid:18224312 PMCid:PMC2235910
15. Suke SG, Kosta P, Negi H. Role of pharmacovigilance in India: An overview. Online journal of public health informatics. 2015;7(2). https://doi.org/10.5210/ojphi.v7i2.5595 PMid:26392851 PMCid:PMC4576445
16. Hodgson J, Marshall A. Pharmacogenomics: will the regulators approve?. Nature biotechnology. 1998 Oct;16(2):13-5. https://doi.org/10.1038/5143
17. Warren LL, Hughes AR, Lai EH, Zaykin DV, Haneline SA, Bansal AT, Wooster AW, Spreen WR, Hernandez JE, Scott TR, Roses AD. Use of pairwise marker combination and recursive partitioning in a pharmacogenetic genome-wide scan. The Pharmacogenomics Journal. 2007 Jun;7(3):180-9. https://doi.org/10.1038/sj.tpj.6500414 PMid:16969363
18. Berlin JA, Glasser SC, Ellenberg SS. Adverse event detection in drug development: recommendations and obligations beyond phase 3. American journal of public health. 2008 Aug;98(8):1366-71. https://doi.org/10.2105/AJPH.2007.124537 PMid:18556607 PMCid:PMC2446471
19. Kahn MG, Ranade D. The impact of electronic medical records data sources on an adverse drug event quality measure. Journal of the American Medical Informatics Association. 2010 Mar 1;17(2):185-91. https://doi.org/10.1136/jamia.2009.002451 PMid:20190062 PMCid:PMC3000787
20. Whitebread S, Hamon J, Bojanic D, Urban L. Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development. Drug discovery today. 2005 Nov 1;10(21):1421-33. https://doi.org/10.1016/S1359-6446(05)03632-9 PMid:16243262
21. McClure DL. Improving drug safety: active surveillance systems should be paramount. Pharmaceutical medicine. 2009 Jun;23:127-30. https://doi.org/10.1007/BF03256760
22. Shibata A, Hauben M. Pharmacovigilance, signal detection and signal intelligence overview. In14th International Conference on Information Fusion 2011 Jul 5 (pp. 1-7). IEEE.
23. Lopes P, Nunes T, Campos D, Furlong LI, Bauer-Mehren A, Sanz F, Carrascosa MC, Mestres J, Kors J, Singh B, van Mulligen E. Gathering and exploring scientific knowledge in pharmacovigilance. PLoS One. 2013 Dec 11;8(12):e83016. https://doi.org/10.1371/journal.pone.0083016 PMid:24349421 PMCid:PMC3859628
24. Härmark L, Van Grootheest AC. Pharmacovigilance: methods, recent developments and future perspectives. European journal of clinical pharmacology. 2008 Aug;64:743-52. https://doi.org/10.1007/s00228-008-0475-9 PMid:18523760
25. Xu L, Anchordoquy T. Drug delivery trends in clinical trials and translational medicine: Challenges and opportunities in the delivery of nucleic acid‐based therapeutics. Journal of pharmaceutical sciences. 2011 Jan;100(1):38-52. https://doi.org/10.1002/jps.22243 PMid:20575003 PMCid:PMC3303188
26. Coloma PM, Schuemie MJ, Trifiro G, Gini R, Herings R, Hippisley‐Cox J, Mazzaglia G, Giaquinto C, Corrao G, Pedersen L, van der Lei J. Combining electronic healthcare databases in Europe to allow for large‐scale drug safety monitoring: the EU‐ADR Project. Pharmacoepidemiology and drug safety. 2011 Jan;20(1):1-1. https://doi.org/10.1002/pds.2053 PMid:21182150
27. Robb MA, Racoosin JA, Sherman RE, Gross TP, Ball R, Reichman ME, Midthun K, Woodcock J. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety. Pharmacoepidemiology and drug safety. 2012 Jan 1;21(1):9. https://doi.org/10.1002/pds.2311 PMid:22262587
28. Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiology and drug safety. 2003 Jan;12(1):17-29. https://doi.org/10.1002/pds.773 PMid:12616844
29. Kurz X, Slattery J, Addis A, Durand J, Segec A, Skibicka I, Szmigiel A, Hidalgo-Simon A. The EudraVigilance database of spontaneous adverse reactions as a tool for H1N1 vaccine safety monitoring. InPharmacoepidemiology and Drug Safety 2010 Aug 1 (Vol. 19, pp. S330-S331). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY-BLACKWELL.
30. Gupta SK. Drug discovery and clinical research. JP Medical Ltd; 2011. https://doi.org/10.5005/jp/books/11216_5
31. Yom-Tov E, Gabrilovich E. Postmarket drug surveillance without trial costs: discovery of adverse drug reactions through large-scale analysis of web search queries. Journal of medical Internet research. 2013 Jun 18;15(6):e2614. https://doi.org/10.2196/jmir.2614 PMid:23778053 PMCid:PMC3713931
32. Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiology and drug safety. 2009 Jun;18(6):427-36. https://doi.org/10.1002/pds.1742 PMid:19358225
33. Biswas P. Pharmacovigilance in Asia. Journal of Pharmacology and Pharmacotherapeutics. 2013 Dec;4(1_suppl):S7-19. https://doi.org/10.4103/0976-500X.120941 PMid:24347987 PMCid:PMC3853674
34. Kumar S, Baldi A. Pharmacovigilance in India: perspectives and prospects. Journal of Drug Delivery and Therapeutics. 2013 Aug 11;3(4):237-46. https://doi.org/10.22270/jddt.v3i4.619
35. Andrews EB, Moore N, editors. Mann's pharmacovigilance. John Wiley & Sons; 2014 Jun 23. https://doi.org/10.1002/9781118820186
36. Tripathy NR, Basha S, Jain R, Shetty S, Ramachandran A. Exenatide and acute pancreatitis. J Assoc Physicians India. 2008 Dec 1;56(6):987-8.
37. Palanisamy S, Kottur SG, Kumaran A, Rajasekaran A. A study on assessment of knowledge about adverse drug reactions. Der Pharmacia Lettre. 2013;5(1):41-52.
38. Lindquist M. VigiBase, the WHO global ICSR database system: basic facts. Drug Information Journal. 2008 Sep;42(5):409-19. https://doi.org/10.1177/009286150804200501
39. Al-Riyami AZ, Al-Hashmi S, Al-Arimi Z, Wadsworth LD, Al-Rawas A, Al-Khabori M, Daar S. Recognition, investigation and management of acute transfusion reactions: consensus guidelines for Oman. Sultan Qaboos University Medical Journal. 2014 Aug;14(3):e306.
40. Wu TY, Jen MH, Bottle A, Molokhia M, Aylin P, Bell D, Majeed A. Ten-year trends in hospital admissions for adverse drug reactions in England 1999-2009. Journal of the Royal Society of Medicine. 2010 Jun 1;103(6):239-50. https://doi.org/10.1258/jrsm.2010.100113 PMid:20513902 PMCid:PMC2878823
41. Runciman WB, Roughead EE, Semple SJ, Adams RJ. Adverse drug events and medication errors in Australia. International Journal for Quality in Health Care. 2003 Dec 1;15(suppl_1):i49-59. https://doi.org/10.1093/intqhc/mzg085 PMid:14660523
42. Hamilton HJ, Gallagher PF, O'Mahony D. Inappropriate prescribing and adverse drug events in older people. BMC geriatrics. 2009 Dec;9:1-4. https://doi.org/10.1186/1471-2318-9-5 PMid:19175914 PMCid:PMC2642820
43. Moore N, Lecointre D, Noblet C, Mabille M. Frequency and cost of serious adverse drug reactions in a department of general medicine. British journal of clinical pharmacology. 1998 Mar;45(3):301-8. https://doi.org/10.1046/j.1365-2125.1998.00667.x PMid:9517375 PMCid:PMC1873369
44. Griffin JP. The evolution of human medicines control from a national to an international perspective. Adverse drug reactions and toxicological reviews. 1998 Mar 1;17(1):19-50.
45. Biswas P, Biswas AK. Setting standards for proactive pharmacovigilance in India: The way forward. Indian journal of pharmacology. 2007 May 1;39(3):124. https://doi.org/10.4103/0253-7613.33431
46. Ramesh M, Pandit J, Parthasarathi G. Adverse drug reactions in a south Indian hospital-their severity and cost involved. Pharmacoepidemiology and drug safety. 2003 Dec;12(8):687-92. https://doi.org/10.1002/pds.871 PMid:14762985
47. Thota P, Vivekanandan K, Prakash J, Singh S, Singh GN. Weight gain in association with insulin use-an analysis of individual case safety reports an Indian database. J Pharmacovigil. 2014;2:119. https://doi.org/10.4172/2329-6887.1000119
Crossmark
Statistics
207 Views | 17 Downloads
How to Cite
1.
Mansuri A, Zaman TU. Pharmacovigilance: A Necessary Tool for Drug Safety Monitoring Globally. JDDT [Internet]. 15Apr.2024 [cited 12Jul.2024];14(4):96-03. Available from: https://jddtonline.info/index.php/jddt/article/view/6516